Clinical Trial Update: Advancing Renal TRANSplant eFficacy and Safety Outcomes With an eveRolimus-based regiMen (TRANSFORM) [Phase 4]

View source ↗

Summary

Phase 4 trial update evaluating the efficacy and safety of an everolimus-based regimen in renal transplant recipients (TRANSFORM).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• End-stage Renal Disease
• Renal Transplantation

Drugs mentioned

• Afinitor (everolimus)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: End Stage Renal Disease (ESRD), Chronic Kidney Disease (CKD) | Phase 4 | Status: COMPLETED | Results posted: 2019-01-30